Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea - Wikidata - wikimedia - TriplyDB

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

http://www.wikidata.org/entity/Q57318858

about

Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach Hydroxyurea could be a good clinically relevant iron chelator Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.How I use hydroxyurea to treat young patients with sickle cell anemia.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea High-density SNP genotyping to define beta-globin locus haplotypes.Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.Fetal hemoglobin in sickle cell anemia Pharmacotherapy in sickle cell disease--state of the art and future prospects Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.Genetic modifiers of sickle cell disease Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.Pharmacogenomics and therapeutics of hemoglobinopathies.Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease Differences in the clinical and genotypic presentation of sickle cell disease around the world.Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment.Role of stem cell factor in the reactivation of human fetal hemoglobin.Emerging science of hydroxyurea therapy for pediatric sickle cell disease.The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders.Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.cAMP response element-binding protein 1 is required for hydroxyurea-mediated induction of γ-globin expression in K562 cells.Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.Toward the prediction of FBPase inhibitory activity using chemoinformatic methods.Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience.Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients Pharmacogenomics of sickle cell disease: steps toward personalized medicine.Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.A single nucleotide polymorphism in the HBBP1 gene in the human β-globin locus is associated with a mild β-thalassemia disease phenotype.Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.

P2860

Q24289319-0B49CC8C-D82A-4606-A404-0558E6092D57 Q28536619-43B145CE-EADB-4DC4-A67D-C9EA7063EDE8 Q33706399-202F5FC8-D132-44EB-8385-C5B1B08A5987 Q33791764-D94BCE9B-D105-42A0-A010-85A662B71EB0 Q33985120-3DCFB62B-4311-4EA6-9019-D11ECF9AC3FF Q34131354-E0F8CF3E-D89A-401C-B45F-89154BDA6637 Q34322542-3B202902-8DEF-440B-AC33-7CE036E46692 Q34424787-F91B55BB-0B24-4CCF-BFC8-762F67EDABBA Q34586227-6D0DF782-7951-4BA1-B684-10616D82BD1B Q34610691-538A212A-24E5-480D-8C60-DBC15130039A Q35053910-3EF04CF9-21F5-4187-9633-16B10E9A35CA Q35114500-A2249E9F-B2F4-41FF-AEE1-E31885C443EE Q35220342-4E887DC5-61EB-4117-B191-06FACF5EF76E Q35230853-111CA5E8-2DCF-4425-8B19-7DE77001C5F5 Q35525659-91BD6CC8-70FC-4D08-84AA-72EA7F871577 Q35571071-49D27730-7EF0-4F5B-9E22-36150511D71A Q36035471-275377CF-A414-4839-A634-FC548F69AE60 Q36591800-75E53FEE-9DAD-41EE-ADE7-86E61071C343 Q37084743-820FBE16-02B3-405C-9D44-B54CBE451285 Q37415993-871FA7D3-27CF-4B4B-85FB-BF973F0C3E8E Q37524888-531B8734-0217-4070-9ECD-CB8C25A868E8 Q37620798-E97300B9-528E-4EA2-B081-0E323721C5D9 Q37810126-A6FC446B-9CC2-43B2-9C22-A259D9FC8D3B Q37854469-3D01DDEB-4898-4D85-9952-890A66D402CC Q38164192-63DF4605-4A0D-4B0E-9910-B641409D33FC Q38176054-D70C35FD-D49C-4FF6-A38D-6C8ED55A53E7 Q38186032-D6572051-3586-4E53-99A6-EAC53FF81F27 Q38243173-C526D72A-036B-4744-A822-43EAE8B12DF0 Q38956275-A54C94A3-4A81-48F5-8608-EE8750F41EDA Q39196524-FC4D17E0-857B-4A9B-AFAB-E09F19143B33 Q39370653-33A1B287-A610-4B22-AC93-AB43BA7A1104 Q40245190-5EE1615E-56DD-4D3A-91AA-24200DE1C244 Q42237895-46E7E019-2FD3-45B6-9CAA-B659E918CB12 Q42427838-5789E44A-1431-4B88-9171-4EFD6C3231EF Q42643812-67AA13DA-445E-4F0B-BA5A-4C61C62B1909 Q42964401-49CA5BAD-508C-424C-815D-0101086F953F Q45874809-451141B7-18A0-4EB5-802B-FAB5EB328711 Q45936952-9AB748AB-3F73-4D6A-B7FB-D6BF572C3704 Q46537338-3510F05B-F6BE-4724-9F49-9A85C8CDC330 Q46906091-32063EC2-4AC3-46C0-88D5-2777ECE7A0D8

P2860

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

http://www.wikidata.org/entity/Q57318858

description

article

@en

im Februar 2007 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2007

@uk

name

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

@en

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

@nl

type

label

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

@en

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

@nl

prefLabel

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

@en

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

@nl

P1433

Q57318858-AD5C18C2-C80F-44FC-B7D6-70A3EB010F51

P1476

Q57318858-AFBC6BC5-6476-48EB-BF31-351EA8989813

P2093

Q57318858-00641FC9-4114-4549-98EA-533F4C0BAC3C

Q57318858-131F3C2E-76A9-4596-AC86-81E572B85127

Q57318858-4708FC0A-AB92-477C-8486-02D3A1CF4865

Q57318858-4C935616-DF37-478B-82FF-DAEF9C625BBE

Q57318858-CE8E564F-E5AA-41DB-89AC-E10E88B335A7

P2860

Q57318858-1F304B3D-53C5-46DD-8F49-F2D4C93072F5

Q57318858-21004CBD-FB34-49BC-8A98-B22E612C0248

Q57318858-224957DF-4B6D-45BC-A8DA-B47543F565D1

Q57318858-26DDC033-A788-4009-A6C8-985864A350B6

Q57318858-2DBBD44E-9F98-46F4-A514-F0AF5D9874B8

Q57318858-2DFC46C6-04BE-463C-BB5D-ABB41A876FA3

Q57318858-33EC9B65-9A44-4468-997C-9D8D99EEF15C

Q57318858-39400F2D-3CB5-457C-941E-B245C52AA665

Q57318858-430150DA-2ECD-4D99-A26C-1C33025D9044

Q57318858-4E8E53C5-0CE2-48F2-B51A-5AB54E112B1B

P2888

Q57318858-84B0F925-A08E-4CA0-A0F4-F81B455CECC3

P304

Q57318858-3B987273-02FF-4BDC-868B-F1D4C8974638

P31

Q57318858-36EF8140-9663-447E-9B89-CCC5BCDB61D6

P356

Q57318858-BC2848FC-6068-48EF-B41C-64918F361194

P433

Q57318858-09B6D1EB-B1C3-4487-A2DD-220D556B16D5

P478

Q57318858-916F04B6-0C0D-48D1-BC7A-98F6ABF84BF8

P50

Q57318858-351F7F5A-5FE1-4CE8-B932-07E326E462F1

Q57318858-F784EC5C-F13C-4540-BA8C-2FE473E7AFBE

P577

Q57318858-67A36DCA-7AA2-4F2E-B8AA-D76E13AEFDF7

P698

Q57318858-9B3F8AE8-8B3C-477E-9EEB-DE23B5127251

P356

P1433

The Pharmacogenomics Journal

P1476

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

@en

P2093

Baldwin CT

http://www.w3.org/2001/XMLSchema#string

Farrell JJ

http://www.w3.org/2001/XMLSchema#string

Kutlar A

http://www.w3.org/2001/XMLSchema#string

Ma Q

http://www.w3.org/2001/XMLSchema#string

Wyszynski DF

http://www.w3.org/2001/XMLSchema#string

P2860

Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF

The "beta-like-globin" gene domain in human erythroid cells

The International HapMap Project

Haploview: analysis and visualization of LD and haplotype maps

Score tests for association between traits and haplotypes when linkage phase is ambiguous

On the allelic spectrum of human disease

Invited commentary: Testing for Hardy-Weinberg disequilibrium using a genome single-nucleotide polymorphism scan based on cases only.

Control of globin gene expression during development and erythroid differentiation

In vivo modulation of human beta-globin gene switching.

P2888

P304

386-394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.TPJ.6500433

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Martin H Steinberg

Lindsay A. Farrer

P577

2007-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17299377

http://www.w3.org/2001/XMLSchema#string